BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, December 6, 2025
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 14, 2020
View Archived Issues
Copper escort alleviates Menkes disease
Read More
Immunity-related pathways contribute to the genetic burden of asthma pathology, new GWAS shows
Read More
Phase I data presented for LC51-0255
Read More
TBR-760 results in complete arrested tumor growth in mouse model of NFPA
Read More
Discovery of potent BACE1 inhibitor, AM-6494
Read More
First patient dosed in phase I/II study of TJD5 in China
Read More
Sunovion discontinues development of dasotraline
Read More
New androgen receptor antagonists described by ESSA Pharma
Read More
Enrollment of first patient in phase III study of viltolarsen in boys with DMD
Read More
Insilico Medicine Hong Kong discovers DDR1 inhibitors
Read More
Ascletis receives IND approval in China for clinical development of ASC-41 in NASH
Read More
Nurix Therapeutics patents Bruton tyrosine kinase-degrading compounds
Read More
ViiV Healthcare discovers new HIV-1 Capsid protein p24 assembly inhibitors
Read More
New adenosine A2A and A2B receptors disclosed by Merck KGaA
Read More
miRNA-126-5p circulating levels are decreased in severe sepsis
Read More
Improved therapeutic index could reduce opioid toxicity
Read More
Blueprint Medicines' BLU-847 shows activity against wild-type and mutant tyrosine kinase receptors
Read More
Immunic receives approval to begin phase II study of IMU-838 for COVID-19
Read More
SHISA4 expression proven useful to monitor nintedanib therapy in patients with IPF
Read More
Merck & Co. reports phase II data on MK-6482 for VHL disease-associated ccRCC
Read More
Vyriad opens phase II trial of Voyager-V1 in combination with cemiplimab for cancer
Read More
Viela reports interim phase Ib data on VIB-7734 in cutaneous lupus erythematosus
Read More